Press Releases Tonix Pharmaceuticals Nasdaq

Equities

TNXP

US8902608624

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-02-04 pm EST			5-day change	1st Jan Change
0.3222 ^USD	-2.36%		+2.32%	-20.05%

Apr. 01	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Apr. 01	Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase	Apr. 24	AQ
Tonix Pharmaceuticals : Investor Presentation April 2024	Apr. 19	PU
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	Apr. 09	PU
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	Apr. 01	AQ
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering	Mar. 28	AQ
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome	Mar. 25	AQ
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting	Mar. 21	AQ
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia	Mar. 20	AQ
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024	Mar. 19	AQ
Tonix Pharmaceuticals : TNX-102 SL for Fibromyalgia and Long COVID	Mar. 12	PU
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring	Mar. 12	AQ
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia	Mar. 11	AQ
Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia	Mar. 07	AQ
Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy	Mar. 07	AQ
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 Supports Monthly i.v. dosing in Humans	Mar. 06	AQ
Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia	Mar. 06	AQ
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans	Mar. 05	AQ
New to the Street TV Series on Bloomberg and Fox Business, Innovative Companies Spotlighted: ACXP, TNXP, PETV, SWISF, GEVI, CLNV	Mar. 01	AQ
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 in Healthy Volunteers	Feb. 29	AQ
Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia	Feb. 29	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tonix Pharmaceuticals Nasdaq

Equities

TNXP

US8902608624

Press Releases

Filters